Opendata, web and dolomites

SUMMA SIGNED

Stimulating mir-106b expression to regenerate the myocardium

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SUMMA" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 149˙875 €
 EC max contribution 149˙875 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 149˙875.00

Map

 Project objective

Most people who develop ischemic HF have (or had) an ischemic heart condition first (e.g. myocardial infarction, MI). Restoring damaged heart muscle tissue therefore represents a fundamental mechanistic strategy to treat HF. Cardiac regeneration after ischemic damage can be achieved by stimulating the proliferation of already existing (endogenous) cardiomyocytes rather than having to rely on the implantation of exogenous cells (i.e. stem cell therapy). Compelling evidence supports that expanding the endogenous cardiomyocyte proliferation capacity by gene therapy appears to represent a promising approach to achieve endogenous cardiac regeneration. Species of non-coding RNA molecules, microRNAs, have been demonstrated to stimulate cardiomyocyte proliferation and the recognition of microRNAs as potential regenerative targets marks a major step towards fundamentally new therapeutic concepts that SUMMA addresses in ischemic heart disease. In the context of the ERC-Starting Grant project CALMIRS, we identified the miR-106b~25 cluster with high potential as new target for therapy to stimulate regeneration of the heart by promoting cardiomyocyte proliferation. Within SUMMA, we aim to advance these valuable research results on microRNA cardiac gene therapy in mice towards commercial proof-of-concept. During this project, proof-of-concept efficacy studies in a large animal (e.g. porcine) model of cardiac ischemia will be performed, while simultaneously market research, IP strategy development and business development activities take place to maximize the value of the project’s results. Different business models will be studied in terms of market research, IP strategy and business development to eventually consolidate a commercial strategy and business case for presenting our business proposition to strategic partners or venture capitalists.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

ULIGHT (2020)

Bright and Compact Deep Ultraviolet Light Sources for Healthcare and Industry

Read More